Biotech Merger Drives Shares Up
Boundless Bio and Serapha Bio Confirm All-Stock Merger, Shares Surge Over 95%
Key Points
A roughly $230 million private placement to fund operations into 2029 is being led by RTW Investments and RA Capital Management, with a syndicate including Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, LifeSci Venture Partners, Logos Capital, Balyasny Asset Management and Eventide Asset Management; about $138 million has already been funded in a Series A, with roughly $92 million expected to close near the merger.
Before the deal closes, Boundless Bio trades with an approximate market cap of $31.5 million and a stock price around $1.40, underscoring the significant dilution risk of the all-stock merger.
Boundless Bio’s strategy centers on its Spyglass platform and the development of BBI-940, an ecDNA-targeting cancer drug candidate, highlighting the merger’s emphasis on ecDNA biology as a cancer vulnerability.
The merger has unanimous board approval and is targeted to close in the fourth quarter of 2026, according to the reporting on the deal.
Boundless Bio and privately held Serapha Bio announced a definitive all-stock merger on June 23, 2026, that will effectively hand control of the combined company to Serapha shareholders. The deal comes with a $230 million private placement and will send the ticker from BOLD to AATD on Nasdaq, according to GlobeNewswire. Boundless Bio shares surged more than 95% in premarket trading on the news.
The merger is a sharp pivot for Boundless Bio, which has struggled since its $100 million IPO in early 2024. The stock had fallen to about $1.40 per share — a market cap of just $31.5 million — before the announcement, according to Investing.com.
Boundless Bio's Cancer Drug Program Collapses Before Merger
Boundless Bio built its business around a technology called the Spyglass platform, which targeted extrachromosomal DNA — or ecDNA — a driver of cancer. The company's lead cancer drug, BBI-940, entered Phase 1 trials in early 2026. But early data showed human bioavailability far below what lab tests had predicted, making the drug nonviable, according to TipRanks.
CEO Zachary Hornby said the early clinical data for BBI-940 "did not support continuing to advance this program," according to Stock Titan. Two earlier drugs, BBI-825 and BBI-335, had also been scrapped due to poor drug behavior in the body. Hornby will step down on July 1, 2026, with Chief Legal Officer Jessica Oien taking over as principal executive officer through the transition.
Serapha Brings a Gene-Editing Lung Disease Drug to the Table
The new company will focus entirely on SERP-01, Serapha's lead drug for Alpha-1 Antitrypsin Deficiency, or AATD. AATD is a genetic disorder that damages the lungs and liver. It affects roughly 100,000 people in the U.S., according to Investing.com. SERP-01 uses in vivo base editing — a technique that corrects a single letter in a patient's DNA without removing it from the body.
Serapha licensed SERP-01 from Chinese biotech YolTech Therapeutics, which keeps rights in Greater China and is eligible for more than $2 billion in milestone payments plus royalties, according to GlobeNewswire. Early proof-of-concept data showed SERP-01 restored serum AAT protein to normal levels. The plan is to move the drug from early trials in Shanghai into global Phase 2 and 3 studies.
$230 Million Raised as Boundless Shareholders Get Bought Out
RA Capital Management and RTW Investments are leading the $230 million private placement. The syndicate also includes Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, LifeSci Venture Partners, Logos Capital, Balyasny Asset Management, and Eventide Asset Management, according to GlobeNewswire. About $138 million was already funded in a Series A round. The remaining $92 million is expected to close near the merger date.
Chris Morrison of RA Capital said "Serapha will hit the ground running" with help from RA Capital's Blackbird clinical development accelerator, according to Stock Titan. The cash is expected to fund operations into the second half of 2029, covering Phase 2 completion and the start of Phase 3. Before the deal closes, Boundless will pay its current shareholders a one-time cash dividend of $44 million to $48 million.
Boundless Shareholders Left With 3.7% as AATD Race Gets Crowded
When the deal closes, Serapha shareholders will own about 96.3% of the combined company. Boundless shareholders will hold just 3.69%, according to Nasdaq. That is a steep dilution for current BOLD holders, even after the cash dividend. The deal has unanimous board approval and is set to close in Q4 2026. Boundless is also cutting 75% of its workforce, with one-time charges of $3 million to $5 million, according to Stock Titan.
The new Serapha Bio enters a competitive field. Beam Therapeutics, CRISPR Therapeutics, and AIRNA are all working on AATD treatments using different gene-editing approaches. Analysts at TipRanks remain neutral on BOLD shares, citing "sizable ongoing losses" and uncertainty until Serapha's clinical data matures, according to TipRanks.
Sentiment
Mostly PositivePublishers
13
Articles
46
Reach
59
